title: [Benefit assessment of drugs].
abstract: In Germany, new drugs are subject to a benefit assessment at the time of their market access. This "early benefit assessment" is the method primarily used for the benefit assessment of pharmaceuticals in Germany. While for the authorization of a drug a positive risk-benefit ratio is sufficient, early benefit assessment examines whether the new drug has an added benefit compared with other therapies, and thus differs significantly from authorization. For the evaluation, the manufacturer is required to submit a dossier, which must contain all the relevant studies. Early benefit assessment is very transparent in international comparisons, because all the relevant data and the evaluation report will be published. The assessment is carried out with regard to the evidence-based standard of care (the "appropriate comparator"). If the new drug is found to have an additional benefit, the extent of this added benefit is assessed. In addition, groups of patients should be identified with the particular extent of the added benefit. Therefore, subgroup analyses have to be carried out frequently. Often, for new drugs, only registration studies are available. General requirements for such studies (e.g., placebo comparison, endpoints) and decisions regarding the approval process (e.g., dosage regimens) can affect the level of confidence of these studies in the benefit assessment. Joint scientific advice by regulatory authorities and HTA (health technology assessment) agencies are provided to solve this problem. However, this is not possible without additional expense for the pharmaceutical companies.
authors.affiliation: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Im Mediapark 8, 50670, Köln, Deutschland, thomas.kaiser@iqwig.de.
authors.forename: Thomas
authors.initials: T
authors.lastname: Kaiser
authors.forename: V
authors.initials: V
authors.lastname: Vervölgyi
authors.forename: B
authors.initials: B
authors.lastname: Wieseler
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence* / Q000379:methods; D003362:Cost-Benefit Analysis / Q000331:legislation & jurisprudence* / Q000379:methods; D017277:Drug Approval / Q000331:legislation & jurisprudence* / Q000379:methods; D019317:Evidence-Based Medicine / Q000331:legislation & jurisprudence / Q000379:methods; D005858:Germany; D017063:Outcome Assessment, Health Care / Q000331:legislation & jurisprudence* / Q000379:methods; D018570:Risk Assessment / Q000331:legislation & jurisprudence* / Q000379:methods; D016896:Treatment Outcome